Specific SGLT2 Inhibitor Drugs used to treat Type-2 Diabetes may cause Fournier's Gangrene of the genitals
Our attorneys are actively pursuing these casesCall now
to find out if you qualify
In August 2018, the FDA warned doctors and patients that cases of Fournier’s gangrene - a rare but serious infection of the genitals - had been reported with certain types of Type 2 Diabetes medications known as SGLT2 inhibitors. The FDA stated that from March 2013 to May 2018, the agency identified 12 cases of Fournier’s gangrene in patients taking an SGLT2 inhibitor such as Invokamet. All 12 patients were hospitalized and required surgery.
Oral diabetes medicines which make up the SGLT2 inhibitors class of drugs include: Invokana, Farxiga, Jardiance, Invokamet, Xigduo, Glyxambi, Synjardy, Qtern, Steglatro, Steglujan, and Segluromet, among others.
A recent study published in the Annals of Internal Medicine linked 'flesh-eating' genital infections to certain SGLT2 Inhibitors and urged doctors to look for signs of a rare, potentially fatal genital infection in patients taking certain diabetes drugs.
If you or a loved one used an SGLT2 Inhibitor Drug and later experienced:
You may be entitled to significant compensation from the manufacturer.
There are time deadlines to file a claim so don’t wait – act now.
Free Diabetes Medications Legal Consultation